NeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia - NeOnc

▤ Summary

NeOnc Technologies received two NIH STTR grants totaling $2.5 million to support development of its NEO212 cancer therapy. One grant funds preclinical feasibility work in acute myelogenous leukemia, while the larger grant supports expansion into newly diagnosed gliomas. The company says the funding will help it move toward Phase 2 trial initiation after completing Phase 1 work. The release also highlights NeOnc’s broader CNS oncology pipeline and its academic collaboration with USC.

$ Funding

▦ Linked Companies